Pfizer beats Q1 profit estimates on demand for newly acquired drugs, COVID products
The company said it expects significantly lower sales contributions from COVID products in the second quarter from the first quarter.
Bengaluru: Pfizer Inc on Tuesday beat analysts' estimates for first-quarter profit on strong demand for its newly acquired drugs and steady demand for its COVID products, sending its shares up nearly three per cent before the bell. The company has said it expects 2023 to be a "transition year" for its COVID products, before potential returning to growth in 2024.Sales of its COVID-19...
Bengaluru: Pfizer Inc on Tuesday beat analysts' estimates for first-quarter profit on strong demand for its newly acquired drugs and steady demand for its COVID products, sending its shares up nearly three per cent before the bell. The company has said it expects 2023 to be a "transition year" for its COVID products, before potential returning to growth in 2024.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd